Qingwei Powder Veterinary Grade API is supplied as a white to off-white crystalline powder with polymorphic identity confirmed by X-ray powder diffraction against the manufacturer’s reference diffractogram. The material is assigned internal code QW-VG-API and is released as an active pharmaceutical starting material for further pharmaceutical processing; it is not a finished veterinary medicinal product and must not be administered directly to animals. Three packaging configurations are available: 25 kg HDPE drum with double LDPE liner for non-sterile oral dosage manufacturing, 5 kg foil-laminated bag for premix and granule lines, and 1 kg gamma-compatible sterile transfer bag for injectable compounding. The powder is specified for incorporation into tablets, injections, capsules, powders, granules, premix, and solutions. Each dosage form imposes a distinct constraint on particle size, bulk density, moisture, bioburden, and endotoxin load; therefore, the product is released in differentiated specification subsets rather than as a single undifferentiated material. Sampling for release testing follows a stratified plan across the top, middle, and bottom of each container, with 10 g composite samples for identity and assay and separate sterile sampling devices for the injectable grade. Unless indicated as a release specification, the processing boundaries in this document are generated from standard veterinary manufacturing practice and do not replace site-specific validation.

Material identity, release specification, and the CoA audit trail

Release of QW-VG-API is governed by a certificate of analysis that includes identity, assay, related substances, residual solvents, moisture, residue on ignition, heavy metals, particle size, bulk and tapped density, and, for sterile or injectable grades, endotoxin and sterility. Representative acceptance criteria are shown in Table 1. Published data for this specific configuration is limited; the table should be read as an example of common veterinary API acceptance limits and must be verified against the approved dossier and the batch-specific CoA. The analytical methods are compendial where applicable; non-compendial methods such as laser diffraction particle size analysis are qualified according to ISO 13320:2020.

Batch-to-batch consistency is monitored by trend charts for particle size D10, D50, and D90, as well as moisture, because these variables directly control downstream die filling and blend uniformity. In production-scale bin blenders of 600 L working volume, segregation tendency remains below detectable visual stratification when D90 is held below 150 µm and the Hausner ratio is 1.25–1.35. The D10 value is not treated as a cosmetic metric; a D10 below 20 µm can contribute to dusting and static adhesion during capsule filling, while a D90 above 150 µm can delay dissolution in low-solubility conditions.

For capsules and oral powders, content uniformity is influenced more by particle size and bulk density than by assay alone. Capsule filling on an automatic tamping machine with a 3 mm dosing disc requires a D90 below 75 µm and a compressibility index below 25% to avoid weight variation beyond ±5%. When the API is intended for powder sachets or oral granules, dry granulation through a roller compactor with a 1.0 mm screen is preferred if the bulk powder exhibits bridging in the feed hopper; this converts the material into flowable granules while maintaining dissolution. Dissolution is evaluated according to USP <711> using apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer where the finished product monograph requires that test. For granules, sieve analysis after granulation should retain no more than 10% on the 840 µm screen and no more than 30% below the 150 µm screen, depending on the final dosing device.

What happens when the API is transferred into sterile injection compounding?

Transfer of QW-VG-API into injectable manufacturing moves the control strategy away from flow and compressibility and toward bioburden, endotoxin, particulate matter, and compatibility with aseptic filtration. The injectable grade is released with endotoxin below 0.5 EU/mg and is tested for sterility when the application is labeled sterile. Reconstitution is carried out in Water for Injection at 20–25°C with low-shear mixing at 200–400 rpm until a clear solution is obtained. The solution is passed through a 0.22 µm PVDF or PES membrane filter and filled under Grade A laminar flow. Terminal sterilization at 121°C for 15 min may be applied only if the finished solution demonstrates no more than 0.5% total impurity increase in a thermal challenge study; otherwise, aseptic processing is required. Particulate matter is controlled to USP <788> limits: not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm for small-volume parenterals. Filter compatibility is evaluated by measuring drug assay recovery before and after passage through the membrane; a loss above 2% indicates adsorption to the filter polymer and requires a different membrane or a formulation adjustment. Published data for this specific configuration is limited, and each injectable formulation must be qualified for filter compatibility, osmolality, pH, and container-closure integrity.

If direct compression is selected, particle size and moisture become release-critical

Direct compression is the most sensitive tablet manufacturing route for QW-VG-API because it does not include a granulation step to correct poor flow or high moisture. Tablet press trials on a rotary press with 16-station tooling and turret speed of 30–60 rpm show that sticking and weight variation increase when loss on drying exceeds 0.5% and when D90 exceeds 150 µm. The API is typically blended with microcrystalline cellulose, crospovidone, and magnesium stearate for 15–20 min in a 300 L V-blender; over-lubrication beyond 5 min after magnesium stearate addition can reduce tablet tensile strength. If wet granulation is required, a high-shear granulator with 2.0 L/kg binder addition and 400 L bowl is used, followed by fluid-bed drying to a final moisture content of 1.0%–2.0%. Tablet hardness is monitored at 80–120 N for standard round concave tooling and friability is maintained below 1.0% according to USP <1216>. The process boundary is narrow; a shift of 0.3% in moisture can alter ejection force and cause picking on the lower punch.

Premix and granule production is governed by homogeneity in medicated feed rather than by tablet compactibility. A 1:100 or 1:1000 pre-blend is prepared in a ribbon blender with 500 kg batch size, and uniformity is assessed by taking 10 samples across the discharge stream. Acceptance is typically ±10% of target assay and an RSD below 5%. Solutions require reconstitution in purified water or buffer with pH adjusted to 4.5–7.5, and clarity is assessed by nephelometric turbidity below 10 NTU. The oral solution grade is not automatically interchangeable with the injectable grade because the latter carries stricter endotoxin and particulate matter requirements. For powders intended for feed mixing, the API is often pre-diluted with lactose monohydrate or calcium carbonate; the choice of diluent changes bulk density and dusting, and must be declared in the premix formulation.

Table 2 summarizes the release-critical tests and principal process boundaries for each finished dosage form.

Feed-grade or technical-grade material does not carry the same endotoxin and cleaning validation package

The veterinary-grade API described here differs from feed-grade and technical-grade Qingwei powder in several measurable ways. Feed-grade material may be released with higher heavy metal limits, no endotoxin testing, and less restrictive residual solvent control; it is not suitable for parenteral or tablet manufacture under cGMP. The QW-VG-API grade is manufactured in dedicated equipment with validated cleaning to prevent cross-contamination and is supported by a veterinary drug master file or equivalent technical package. The particle size distribution is controlled by air-jet milling for injectable use and by mechanical sieving for oral powder and premix use. In comparative blending studies, QW-VG-API demonstrates a residual standard deviation below 2% at a 1:1000 dilution in a 600 L double-cone blender, while unmilled technical powder produces segregation and assay variance above 5%. The most critical difference is in injectable applications, where bacterial endotoxin limits per USP <85> and particulate matter limits per USP <788> create a separate release pathway. In addition, the veterinary-grade powder includes a change-control notification commitment for any modification in milling, packaging, or sterilization that could affect downstream processability.

Storage stability is supported by a retest interval of 36 months when the material is kept in the original unopened container at ≤25°C and ≤60% relative humidity. The drum configuration includes desiccant and oxygen absorber; once opened, the material should be used within 30 days or re-tested for moisture and bioburden. For the injectable grade, single-use packaging is recommended because endotoxin and sterility cannot be re-certified after opening. If the powder is exposed to relative humidity above 60%, it may absorb moisture and should be dried in a vacuum oven at 40–50°C for 4–6 h only when a validated drying protocol exists; drying at higher temperatures can alter the polymorphic form and reduce dissolution.